BackgroundMelanoma Inhibitory Activity 3 regulates the plasma level of LDL cholesterol. The c.3169 + 315G > A single-nucleotide polymorphism of the MIA3 gene has been reported to be associated with serum coronary artery disease (CAD). However, there have been no studies analyzing the association of this polymorphism with CAD in Iranian individuals with CAD.ObjectivesTherefore, in the present study we have investigated the potential protective effect of the rs3008621 MIA3 polymorphism in 188 subjects with and without CAD.Materials and MethodsGenotyping of the MIA3 gene was undertaken using TaqMan real-time PCR in all subjects. Anthropometric and biochemical features, including HDL, LDL, and TG were assessed in all subjects.ResultsThe CAD patients had significantly (P < 0.05) higher BMI and significantly higher levels of TG, LDL, SBP, and DBP, while the level of HDL was lower compared to that of the control group. the MIA3 gene polymorphism was not associated with CAD in our population sample.ConclusionsThe MIA3 polymorphism is unlikely to play an important role in CAD in the Iranian population. However, further studies are needed in a larger population to confirm this.
Endovascular repair is increasingly becoming the main strategy for management of aortic and peripheral aneurysms. Several methods have been introduced to treat aneurysms based on anatomy, coexisting nearby aneurysms and available tools. We presented a 60-year-old man with an isolated large iliac artery aneurysm found incidentally treated using an endovascular approach and obliterating internal iliac artery without early and late complications at 3-year follow-up.
Background: Studies investigating the association between ITPKC rs28493229 polymorphisms and Kawasaki disease (KD) risk found inconsistent data. Thus, we performed this meta-analysis to combine and analyze the available studies to get a precise estimation of the association. Methods: Relevant studies identified in the PubMed, Web of Science, Scopus, and CNKI databases were used to perform a meta-analysis. Pooled odds ratios (OR) with a 95% confidence interval (95% CI) were calculated under fixed- and random-effects models to appraise the association. Results: A total of eight case-control studies with 2,721 KD cases and 5,307 controls were selected. The results showed a statistically significant association between ITPKC rs28493229 polymorphism and an increased risk of KD under all five genetic models, i.e., allele (C vs. G: OR = 1.434, 95% CI 1.209-1.700, P ≤ 0.001), homozygote (CC vs. GG: OR = 2.085, 95% CI 1.423-3.055, P ≤ 0.001), heterozygote (CG vs. GG: OR = 1.530, 95% CI 1.359-1.722, P ≤ 0.001), dominant (CC+CG vs. GG: OR = 1.490, 95% CI 1.229-1.806, P ≤ 0.001), and recessive (CC vs. CG + GG: OR = 1.799, 95% CI 1.231-2.629, P = 0.002) in the overall population. When stratified by country, there was a significant association among Taiwanese. Conclusion: Our meta-analysis results supported that the ITPKC rs28493229 polymorphism is strongly associated with susceptibility to KD.
Introduction: Symptomatic chronic mesenteric ischemia (CMI) is a rare condition that usually occurs due to mesenteric artery stenosis (MAS) with a common incidence. Although the prevalence of symptomatic CMI is less than 2%, MAS is more common in the elderly. Case Presentation: A 60-year-old woman with prolonged eating-related abdominal pain and weight loss treated as cholelithiasis by endoscopic retrograde cholangiography was readmitted by recurrent epigastric pain. At this time, she was reevaluated by computed tomography angiography (CTA), and CMI was confirmed. She was treated with percutaneous mesenteric artery stenting and was discharged without pain. There were no complications or pain after 3 months of follow-up. Conclusions: The most prevalent causes of CMI are atherosclerotic processes, such as hypertension, hyperlipidemia, overweight, metabolic syndrome, and smoking. The diagnosis of CMI is confirmed by CTA. Recently, endovascular treatment by percutaneous mesenteric artery stenting is more common than the surgical approaches because of lower in- and out-hospital complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.